SG11201607368XA - Vaccine delivery systems using yeast cell wall particles - Google Patents

Vaccine delivery systems using yeast cell wall particles

Info

Publication number
SG11201607368XA
SG11201607368XA SG11201607368XA SG11201607368XA SG11201607368XA SG 11201607368X A SG11201607368X A SG 11201607368XA SG 11201607368X A SG11201607368X A SG 11201607368XA SG 11201607368X A SG11201607368X A SG 11201607368XA SG 11201607368X A SG11201607368X A SG 11201607368XA
Authority
SG
Singapore
Prior art keywords
cell wall
delivery systems
yeast cell
vaccine delivery
wall particles
Prior art date
Application number
SG11201607368XA
Other languages
English (en)
Inventor
Thomas E Wagner
Original Assignee
Orbis Health Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbis Health Solutions Llc filed Critical Orbis Health Solutions Llc
Publication of SG11201607368XA publication Critical patent/SG11201607368XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4614Monocytes; Macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464499Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201607368XA 2014-03-05 2015-03-04 Vaccine delivery systems using yeast cell wall particles SG11201607368XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461948503P 2014-03-05 2014-03-05
US201462060124P 2014-10-06 2014-10-06
PCT/US2015/018728 WO2015134606A1 (en) 2014-03-05 2015-03-04 Vaccine delivery systems using yeast cell wall particles

Publications (1)

Publication Number Publication Date
SG11201607368XA true SG11201607368XA (en) 2016-10-28

Family

ID=54055837

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607368XA SG11201607368XA (en) 2014-03-05 2015-03-04 Vaccine delivery systems using yeast cell wall particles

Country Status (9)

Country Link
US (6) US10166195B2 (de)
EP (2) EP3113759B1 (de)
JP (3) JP6797022B2 (de)
KR (1) KR102060858B1 (de)
CN (1) CN106456532B (de)
AU (3) AU2015227226B2 (de)
CA (2) CA2941633C (de)
SG (1) SG11201607368XA (de)
WO (1) WO2015134606A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3113759B1 (de) * 2014-03-05 2021-05-12 Orbis Health Solutions LLC Impfstoffabgabesysteme mit hefezellwandpartikeln
WO2015187966A1 (en) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AU2016304853C1 (en) * 2015-08-11 2023-03-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
CN107233298B (zh) * 2016-03-28 2021-01-22 复旦大学 一种促进蛋白多肽药物口服吸收的酵母细胞壁微粒制剂
CN113143977B (zh) * 2021-04-16 2022-04-05 苏州大学 酵母细胞壁纳米颗粒及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454110A (en) 1982-05-24 1984-06-12 Forsyth Dental Infirmary For Children Self-gelling liquid composition for topical application in the oral cavity
US4563351A (en) 1983-08-01 1986-01-07 Forsyth Dental Infirmary For Children Self-gelling therapeutic compositions for topical application
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
JP3272891B2 (ja) 1994-11-22 2002-04-08 カネボウ株式会社 入浴剤
WO1999030629A1 (en) 1997-12-17 1999-06-24 Hemodynamics, Inc. Sealing media for surgery and wound closure
US20050158856A1 (en) 1999-04-20 2005-07-21 Edelson Richard L. Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
US6342203B2 (en) 1999-10-27 2002-01-29 Dakota Dental Development, Inc. Compositions for dentistry comprising an oil, to repair, restore, adhere to, or protect the surface of a tooth
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
DE60213948T2 (de) 2001-01-18 2007-03-08 Newcastle University Ventures Ltd. Biosensor mit kovalent gebundenen membranüberspannenden proteinen
ES2598109T3 (es) 2001-09-06 2017-01-25 Northwest Biotherapeutics, Inc. Composiciones y métodos para la activación linfocitaria de células dendríticas monocíticas y células T para generar una respuesta Th-1
WO2004014320A2 (en) 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Methods of using beta glucan as a radioprotective agent
US20060165700A1 (en) 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
CN1939335A (zh) * 2002-09-04 2007-04-04 路易斯维尔大学研究基金会 使用β葡聚糖和抗体治疗癌性的方法
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
EP1753529B1 (de) 2004-05-20 2013-08-14 Eden Research Plc Zusammensetzungen, enthaltend ein eine terpenkomponente verkapselndes hohles glucanteilchen oder zellwandteilchen und verfahren zur herstellung und verwendung davon
US8007814B2 (en) 2004-06-16 2011-08-30 University Of Massachusetts Therapy for lysosomal enzyme deficiencies
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
BRPI0516356A (pt) 2004-10-18 2008-09-02 Globeimmune Inc terapia à base de levedura para infecções crÈnicas da hepatite c
US20060140983A1 (en) 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
JP5489462B2 (ja) 2005-10-24 2014-05-14 ユニバーシティ オブ マサチューセッツ 骨病状の遺伝子治療のための組成物およびそれらの使用法
KR101446580B1 (ko) 2005-11-30 2014-10-02 에덴 리서치 피엘씨 테르펜-함유 조성물 및 이들을 제조하고 사용하는 방법
CN101336291A (zh) 2005-12-08 2008-12-31 西北生物治疗药物公司 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法
US7736642B2 (en) 2006-02-02 2010-06-15 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
US20080167268A1 (en) 2006-09-01 2008-07-10 Jun Yan Particulate beta-glucan compositions for regulating dendritic cells
US20100111985A1 (en) 2007-04-25 2010-05-06 Orbis Health Solutions, Llc Vaccine compositions and methods of use
US8389485B2 (en) 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
US8728465B2 (en) 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
WO2011053331A1 (en) 2009-11-02 2011-05-05 Orbis Health Solutions Llc Vaccine compositions and methods of use
BR112012017306A2 (pt) 2010-01-12 2015-09-15 Purdue Research Foundation materiais e métodos para produção de membrana bioinorgânicas que não ocorrem naturalmente associadas e direcionadas à superfície celular
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US9242857B2 (en) * 2010-08-14 2016-01-26 University Of Massachusetts Yeast cell wall particles for receptor-targeted nanoparticle delivery
EP2651520A2 (de) 2010-12-13 2013-10-23 Colgate-Palmolive Company Orale zusammensetzungen
US8926994B2 (en) 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
WO2014093454A1 (en) 2012-12-12 2014-06-19 Orbis Health Solutions, Llc Compositions and methods for tissue regeneration
PH12013000256A1 (en) 2013-08-30 2015-03-09 Anacleto M Argayosa Oral vaccine
EP3113759B1 (de) * 2014-03-05 2021-05-12 Orbis Health Solutions LLC Impfstoffabgabesysteme mit hefezellwandpartikeln
US20180228885A1 (en) 2016-03-04 2018-08-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy

Also Published As

Publication number Publication date
CA2941633C (en) 2021-01-12
KR20160132044A (ko) 2016-11-16
AU2018200092A1 (en) 2018-01-25
WO2015134606A1 (en) 2015-09-11
US10675249B2 (en) 2020-06-09
JP7311560B2 (ja) 2023-07-19
AU2015227226B2 (en) 2017-10-05
US20170065532A1 (en) 2017-03-09
JP2019203004A (ja) 2019-11-28
AU2020203274A1 (en) 2020-06-11
US20220151943A1 (en) 2022-05-19
BR112016020373A2 (pt) 2017-08-15
JP2017507152A (ja) 2017-03-16
AU2015227226A1 (en) 2016-10-27
US11759429B2 (en) 2023-09-19
EP3113759A4 (de) 2017-10-18
JP6914996B2 (ja) 2021-08-04
CA3099413A1 (en) 2015-09-11
US10166195B2 (en) 2019-01-01
JP6797022B2 (ja) 2020-12-09
CN106456532A (zh) 2017-02-22
CA2941633A1 (en) 2015-09-11
US11179343B2 (en) 2021-11-23
AU2018200092B2 (en) 2020-02-27
EP3113759B1 (de) 2021-05-12
EP3932392A1 (de) 2022-01-05
JP2021169495A (ja) 2021-10-28
US20190240162A1 (en) 2019-08-08
US20200069596A1 (en) 2020-03-05
US11826476B2 (en) 2023-11-28
US20200368172A1 (en) 2020-11-26
BR112016020373A8 (pt) 2021-06-29
KR102060858B1 (ko) 2019-12-30
CN106456532B (zh) 2020-07-24
US20170007688A1 (en) 2017-01-12
EP3113759A1 (de) 2017-01-11

Similar Documents

Publication Publication Date Title
EP3188843A4 (de) Elektrostatisches flüssigkeitsausgabesystem
EP3137272C0 (de) Mörtelausgabesystem
LT3188717T (lt) Vaisto forma, apimanti daleles
EP3018745B8 (de) Brennstoffzellensystem
EP3212173A4 (de) Verabreichungssysteme
HK1243340A1 (zh) 透細胞質膜的傳遞
GB201410270D0 (en) Cell delivery system and method
EP3101722A4 (de) Brennstoffzellensystem
PT3136841T (pt) Sistemas de fermentação
GB201419607D0 (en) Fuel delivery system
SG11201700043XA (en) Fuel cell system
EP3214685A4 (de) Brennstoffzellensystem
EP3166671A4 (de) Metallorganische gerüstmaterialien in gasausgabesystemen
SG11201607368XA (en) Vaccine delivery systems using yeast cell wall particles
EP3214687A4 (de) Brennstoffzellensystem
ZA201608085B (en) Grout delivery
IL252972A0 (en) Antigen delivery system
AU2015225914B2 (en) Microneedle based cell delivery
EP3174145A4 (de) Brennstoffzellensystem
GB2533265B (en) Fuel cell system
EP3109932A4 (de) Brennstoffzellensystem
IL247106B (en) Material delivery system
EP3161101A4 (de) Auf treibmittel basierendes chemikalienzufuhrsystem
EP3118922A4 (de) Brennstoffzellensystem
GB2539606B (en) Fuel cell system